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Anthracyclines are amongst the most widely used antineoplastic agents. Nevertheless, their 
use is limited by the risk of cardiotoxicity. Dexrazoxane has been the only approved 
cardioprotectant against anthracycline cardiotoxicity so far. Despite half a century of 
research, the mechanisms of its cardioprotective ability as well as the mechanisms of 
anthracycline toxicity are elusive. In this study, we focused on the study of the molecular 
mechanisms of dexrazoxane cardioprotection. We did not prove the principal role of 
glutathione and related antioxidant enzymes in the pathogenesis of anthracycline 
cardiotoxicity both in the in vitro experiments and in vivo in the samples of left ventricles 
from the well-established model of chronic anthracycline cardiotoxicity in rabbits. Moreover, 
we found that in vitro dexrazoxane is able to protect the isolated neonatal rat 
cardiomyocytes against anthracycline-, but not hydrogen peroxide-induced damage. As 
dexrazoxane is also a catalytic inhibitor of topoisomerase II, we compared its 
cardioprotective ability with two other topoisomerase II catalytic inhibitors, sobuzoxane and 
merbarone. All dexrazoxane, sobuzoxane and merbarone were comparably effective in the 
protection of neonatal rat cardiomyocytes against anthracycline toxicity, but were 
uneffective against oxidative damage. At the same time, the catalytic inhibitors used in this 
study did not compromise the antiproliferative activity of antrhracyclines on the HL-60 cell 
line. The structure-activity relationships of the dexrazoxane cardioprotection are not 
precisely determined, as well as the need of its hydrolysis to the metal-chelating metabolite 
ADR-925. Therefore, we studied the newly synthesized analogues of both dexrazoxane and 
ADR-925 regarding their cardioprotective potential. We found that these novel analogues 
are not protective compared to dexrazoxane, which is probably caused by their inactivity 
regarding topoisomerase II catalytic inhibition. From the data of this study as well as from 
the experimental data of other recent studies we can conclude, that rather than by the 
traditionally proposed oxidative damage, anthracyclines may be cardiotoxic due to their 
interaction with the topoisomerase II in cardiomyocytes. 
 
